{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:58:56Z","timestamp":1769633936421,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Syst Biol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12918-015-0243-2","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T10:04:15Z","timestamp":1452506655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prediction of drugs having opposite effects on disease genes in a directed network"],"prefix":"10.1186","volume":"10","author":[{"given":"Hasun","family":"Yu","sequence":"first","affiliation":[]},{"given":"Sungji","family":"Choo","sequence":"additional","affiliation":[]},{"given":"Junseok","family":"Park","sequence":"additional","affiliation":[]},{"given":"Jinmyung","family":"Jung","sequence":"additional","affiliation":[]},{"given":"Yeeok","family":"Kang","sequence":"additional","affiliation":[]},{"given":"Doheon","family":"Lee","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"issue":"2","key":"243_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","volume":"22","author":"JA DiMasi","year":"2003","unstructured":"DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development costs. J Health Econ. 2003, 22 (2): 151-85. 10.1016\/S0167-6296(02)00126-1.","journal-title":"J Health Econ"},{"issue":"1","key":"243_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J: Clinical development success rates for investigational drugs. Nat Biotechnol. 2014, 32 (1): 40-51. 10.1038\/nbt.2786.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"243_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB: Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004, 3 (8): 673-83. 10.1038\/nrd1468.","journal-title":"Nat Rev Drug Discov"},{"issue":"96","key":"243_CR4","doi-asserted-by":"publisher","first-page":"96ra76","DOI":"10.1126\/scitranslmed.3002648","volume":"3","author":"JT Dudley","year":"2011","unstructured":"Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP: Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011, 3 (96): 96ra76-10.1126\/scitranslmed.3002648.","journal-title":"Sci Transl Med"},{"issue":"8","key":"243_CR5","doi-asserted-by":"publisher","first-page":"e6536","DOI":"10.1371\/journal.pone.0006536","volume":"4","author":"G Hu","year":"2009","unstructured":"Hu G, Agarwal P: Human disease-drug network based on genomic expression profiles. PLoS One. 2009, 4 (8): e6536-10.1371\/journal.pone.0006536.","journal-title":"PLoS One"},{"issue":"5795","key":"243_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ: The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006, 313 (5795): 1929-35. 10.1126\/science.1132939.","journal-title":"Science"},{"issue":"96","key":"243_CR7","doi-asserted-by":"publisher","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","volume":"3","author":"M Sirota","year":"2011","unstructured":"Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A: Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011, 3 (96): 96ra77-10.1126\/scitranslmed.3001318.","journal-title":"Sci Transl Med"},{"issue":"5","key":"243_CR8","doi-asserted-by":"publisher","first-page":"e1002503","DOI":"10.1371\/journal.pcbi.1002503","volume":"8","author":"F Cheng","year":"2012","unstructured":"Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G, et al: Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol. 2012, 8 (5): e1002503-10.1371\/journal.pcbi.1002503.","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"243_CR9","doi-asserted-by":"publisher","first-page":"e60618","DOI":"10.1371\/journal.pone.0060618","volume":"8","author":"D Emig","year":"2013","unstructured":"Emig D, Ivliev A, Pustovalova O, Lancashire L, Bureeva S, Nikolsky Y, et al: Drug target prediction and repositioning using an integrated network-based approach. PLoS One. 2013, 8 (4): e60618-10.1371\/journal.pone.0060618.","journal-title":"PLoS One"},{"issue":"20","key":"243_CR10","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/bioinformatics\/btu403","volume":"30","author":"W Wang","year":"2014","unstructured":"Wang W, Yang S, Zhang X, Li J: Drug repositioning by integrating target information through a heterogeneous network model. Bioinformatics. 2014, 30 (20): 2923-30. 10.1093\/bioinformatics\/btu403.","journal-title":"Bioinformatics"},{"issue":"13","key":"243_CR11","doi-asserted-by":"publisher","first-page":"i126","DOI":"10.1093\/bioinformatics\/btt234","volume":"29","author":"Y Wang","year":"2013","unstructured":"Wang Y, Zeng J: Predicting drug-target interactions using restricted Boltzmann machines. Bioinformatics. 2013, 29 (13): i126-i34. 10.1093\/bioinformatics\/btt234.","journal-title":"Bioinformatics"},{"issue":"1","key":"243_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1758-2946-6-1","volume":"6","author":"A Qabaja","year":"2014","unstructured":"Qabaja A, Alshalalfa M, Alanazi E, Alhajj R: Prediction of novel drug indications using network driven biological data prioritization and integration. J Cheminformatics. 2014, 6 (1): 1-10.1186\/1758-2946-6-1.","journal-title":"J Cheminformatics"},{"issue":"2","key":"243_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.6026\/97320630009089","volume":"9","author":"Y Fukuoka","year":"2013","unstructured":"Fukuoka Y, Takei D, Ogawa H: A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs. Bioinformation. 2013, 9 (2): 89-93. 10.6026\/97320630009089.","journal-title":"Bioinformation"},{"issue":"1","key":"243_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28 (1): 27-30. 10.1093\/nar\/28.1.27.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"243_CR15","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/bioinformatics\/btp167","volume":"25","author":"JD Zhang","year":"2009","unstructured":"Zhang JD, Wiemann S: KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor. Bioinformatics. 2009, 25 (11): 1470-1. 10.1093\/bioinformatics\/btp167.","journal-title":"Bioinformatics"},{"issue":"suppl 1","key":"243_CR16","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al: DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006, 34 (suppl 1): D668-D72. 10.1093\/nar\/gkj067.","journal-title":"Nucleic Acids Res"},{"issue":"suppl 1","key":"243_CR17","doi-asserted-by":"publisher","first-page":"D786","DOI":"10.1093\/nar\/gkn580","volume":"37","author":"AP Davis","year":"2009","unstructured":"Davis AP, Murphy CG, Saraceni-Richards CA, Rosenstein MC, Wiegers TC, Mattingly CJ: Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical\u2013gene\u2013disease networks. Nucleic Acids Res. 2009, 37 (suppl 1): D786-D92. 10.1093\/nar\/gkn580.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"243_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30 (1): 207-10. 10.1093\/nar\/30.1.207.","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"243_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jama.1994.03510380059038","volume":"271","author":"HJ Lowe","year":"1994","unstructured":"Lowe HJ, Barnett GO: Understanding and using the medical subject headings (MeSH) vocabulary to perform literature searches. Jama. 1994, 271 (14): 1103-8. 10.1001\/jama.1994.03510380059038.","journal-title":"Jama"},{"key":"243_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/0-387-29362-0_23","volume-title":"linear models for microarray data. Bioinformatics and computational biology solutions using R and Bioconductor","author":"GK Smyth","year":"2005","unstructured":"Smyth GK. Limma: linear models for microarray data. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005. p. 397\u2013420."},{"issue":"9","key":"243_CR21","doi-asserted-by":"publisher","first-page":"e12336","DOI":"10.1371\/journal.pone.0012336","volume":"5","author":"M Jeanmougin","year":"2010","unstructured":"Jeanmougin M, De Reynies A, Marisa L, Paccard C, Nuel G, Guedj M: Should we abandon the t-test in the analysis of gene expression microarray data: a comparison of variance modeling strategies. PLoS One. 2010, 5 (9): e12336-10.1371\/journal.pone.0012336.","journal-title":"PLoS One"},{"issue":"1","key":"243_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1752-0509-7-50","volume":"7","author":"MD Stobbe","year":"2013","unstructured":"Stobbe MD, Swertz MA, Thiele I, Rengaw T, Van Kampen AH, Moerland PD: Consensus and conflict cards for metabolic pathway databases. BMC Syst Biol. 2013, 7 (1): 50-10.1186\/1752-0509-7-50.","journal-title":"BMC Syst Biol"},{"issue":"Suppl 1","key":"243_CR23","first-page":"15","volume":"S3","author":"S Yoon","year":"2015","unstructured":"Yoon S, Jung J, Yu H, Kwon M, Choo S, Park K et al. Context-based resolution of semantic conflicts in biological pathways. BMC medical informatics and decision making. 2015;15 Suppl 1:S3. doi: 10.1186\/1472-6947-15-S1-S3.","journal-title":"BMC medical informatics and decision making"},{"issue":"7","key":"243_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.it.2013.03.007","volume":"34","author":"AA Ajibade","year":"2013","unstructured":"Ajibade AA, Wang HY, Wang R-F: Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol. 2013, 34 (7): 307-16. 10.1016\/j.it.2013.03.007.","journal-title":"Trends Immunol"},{"issue":"2","key":"243_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1021\/ci800344p","volume":"49","author":"J Scheiber","year":"2009","unstructured":"Scheiber J, Chen B, Milik M, Sukuru SCK, Bender A, Mikhailov D, et al: Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model. 2009, 49 (2): 308-17. 10.1021\/ci800344p.","journal-title":"J Chem Inf Model"},{"issue":"10","key":"243_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nbt1338","volume":"25","author":"MA Y\u0131ld\u0131r\u0131m","year":"2007","unstructured":"Y\u0131ld\u0131r\u0131m MA, Goh K-I, Cusick ME, Barab\u00e1si A-L, Vidal M: Drug\u2014target network. Nat Biotechnol. 2007, 25 (10): 1119-26. 10.1038\/nbt1338.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"243_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.tips.2004.10.001","volume":"25","author":"M Domercq","year":"2004","unstructured":"Domercq M, Matute C: Neuroprotection by tetracyclines. Trends Pharmacol Sci. 2004, 25 (12): 609-12. 10.1016\/j.tips.2004.10.001.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"243_CR28","doi-asserted-by":"publisher","first-page":"e15879","DOI":"10.1371\/journal.pone.0015879","volume":"6","author":"S Rajoria","year":"2011","unstructured":"Rajoria S, Suriano R, George A, Shanmugam A, Schantz SP, Geliebter J, et al: Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3\u2019-diindolylmethane in thyroid cancer. PLoS One. 2011, 6 (1): e15879-10.1371\/journal.pone.0015879.","journal-title":"PLoS One"},{"issue":"4","key":"243_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/MLG.0b013e318031055e","volume":"117","author":"CN Prichard","year":"2007","unstructured":"Prichard CN, Kim S, Yazici YD, Doan DD, Jasser SA, Mandal M, et al: Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope. 2007, 117 (4): 674-9. 10.1097\/MLG.0b013e318031055e.","journal-title":"Laryngoscope"},{"issue":"2","key":"243_CR30","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/1078-0432.CCR-05-1325","volume":"12","author":"S Kim","year":"2006","unstructured":"Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, et al: Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res. 2006, 12 (2): 600-7. 10.1158\/1078-0432.CCR-05-1325.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"243_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/thy.2007.0120","volume":"18","author":"NA Pennell","year":"2008","unstructured":"Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, et al: A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008, 18 (3): 317-23. 10.1089\/thy.2007.0120.","journal-title":"Thyroid"},{"issue":"6","key":"243_CR32","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1210\/jc.2012-3623","volume":"98","author":"F Frasca","year":"2013","unstructured":"Frasca F, Vella V, Nicolosi ML, Messina RL, Giani F, Lotta S, et al: Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. J Clin Endocrinol Metab. 2013, 98 (6): 2502-12. 10.1210\/jc.2012-3623.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"243_CR33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s00280-006-0185-x","volume":"58","author":"J Kurebayashi","year":"2006","unstructured":"Kurebayashi J, Okubo S, Yamamoto Y, Ikeda M, Tanaka K, Otsuki T, et al: Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol. 2006, 58 (4): 460-70. 10.1007\/s00280-006-0185-x.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"243_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/1078155208101212","volume":"15","author":"T Hogan","year":"2009","unstructured":"Hogan T, Jing Jie Y, Williams HJ, Altaha R, Xiaobing L, Qi H: Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract. 2009, 15 (2): 111-7. 10.1177\/1078155208101212.","journal-title":"J Oncol Pharm Pract"},{"issue":"16","key":"243_CR35","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1200\/JCO.2010.34.0216","volume":"29","author":"K Masago","year":"2011","unstructured":"Masago K, Miura M, Toyama Y, Togashi Y, Mishima M: Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. J Clin Oncol. 2011, 29 (16): e465-7. 10.1200\/JCO.2010.34.0216.","journal-title":"J Clin Oncol"},{"issue":"2","key":"243_CR36","first-page":"473","volume":"30","author":"M Landriscina","year":"2010","unstructured":"Landriscina M, Maddalena F, Fabiano A, Piscazzi A, La Macchia O, Cignarelli M: Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Anticancer Res. 2010, 30 (2): 473-80.","journal-title":"Anticancer Res"},{"issue":"suppl 1","key":"243_CR37","first-page":"D54","volume":"33","author":"D Maglott","year":"2005","unstructured":"Maglott D, Ostell J, Pruitt KD, Tatusova T: Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2005, 33 (suppl 1): D54-D8.","journal-title":"Nucleic Acids Res"},{"issue":"Suppl 1","key":"243_CR38","first-page":"5","volume":"S10","author":"S Li","year":"2011","unstructured":"Li S, Zhang B, Zhang N. Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol. 2011;5 Suppl 1:S10. doi: 10.1186\/1752-0509-5-S1-S10.","journal-title":"Environ Health"},{"issue":"12","key":"243_CR39","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1039\/c2mb25267h","volume":"8","author":"J Zou","year":"2012","unstructured":"Zou J, Ji P, Zhao YL, Li LL, Wei YQ, Chen YZ, et al: Neighbor communities in drug combination networks characterize synergistic effect. Mol BioSyst. 2012, 8 (12): 3185-96. 10.1039\/c2mb25267h.","journal-title":"Mol BioSyst"}],"container-title":["BMC Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-015-0243-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12918-015-0243-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-015-0243-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-015-0243-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:00:39Z","timestamp":1630612839000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsystbiol.biomedcentral.com\/articles\/10.1186\/s12918-015-0243-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":39,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1186\/s12918-015-0243-2","relation":{},"ISSN":["1752-0509"],"issn-type":[{"value":"1752-0509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,11]]},"assertion":[{"value":"11 January 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"S2"}}